Influence of renin-angiotensin-aldosterone system blockade on atrial fibrillation course


Cite item

Full Text

Abstract

Despite the great success in understanding of many electrophysiological mechanisms of atrial fibrillation (AF) developing and maintaining, until know there is no universal method of its treatment. Using of antiarrhythmic drugs for sinus rhythm maintaining is limited by its low effectiveness. It is reasonable to suppose that the blockage of renin-angiotensin-aldosterone system can decrease the number of the first episodes of AF and prevent the relapses. The article includes the results of the studies evaluating the effects of inhibitors of angiotensin-converting enzyme and angiotensin II receptors blockers on the development and progress of AF. These drugs can prevent AF and its complications, probably by means of regress of structural and functional remodeling of myocardium.

References

  1. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19.
  2. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
  3. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
  4. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19.
  5. Verdecchia P, Reboldi R, Bentivoglio M, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-23.
  6. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-69.
  7. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction the GISSI-3 data. Heart 2001;86:527-32.
  8. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 1999;100:376-80.
  9. Van den Berg MP, Crijns HJGM, van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation J Card Fail 1995;1:355-63.
  10. Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction Circulation 2003;107:2926.
  11. Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartanresults from the CHARM study. J Am Coll Cardiol 2004;43(Suppl. A):222A.
  12. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999;353:611-16.
  13. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999;354:1751-56.
  14. De Simone A, De Pasquale M, De Matteis C, et al. Verapamil Plus Antiarrhythmic Drugs Reduce Atrial Fibrillation Recurrences After an Electrical Cardioversion (VEPARAF study). Eur Heart J 2003;24:1425-29.
  15. Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-69.
  16. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-98.
  17. Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002;106:331-36.
  18. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
  19. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardia-induced congestive heart failure. Circulation 2001;104:2608-14.
  20. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002;54:247-58.
  21. Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volumeimportant risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001;76:467-75.
  22. Vaziri SM, Larson MG, Benjamin EJ, et al. Echocardiographic predictors of nonrheumatic atrial fibrillation the Framingham Heart Study. Circulation 1994;89:724-30.
  23. Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-71.
  24. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-95.
  25. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997;96:1686-95.
  26. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
  27. Shi Y, Ducharme A, Li D, Gaspo R, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001;52:217-25.
  28. Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs atrial remodeling of a different sort. Circulation 1999;100:87-95.
  29. Shi Y, Tardif J-C, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-61.
  30. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.
  31. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2333&mid=1085056570&magid=175&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies